Printer Friendly

Scientists provide overview of multistem clinical trial in Japan.

CLEVELAND, February 23, 2017 -- Athersys, Inc. (ATHX) announced that a Japanese researcher presented data on the outcomes of a clinical trial in Japan featuring its MultiStem cell therapy treatment for ischemic stroke.

Athersys and Healios K.K. entered into a license agreement in January 2016 and have been collaborating on the development and commercialization of MultiStem for the treatment of stroke in Japan.

Athersys completed a Phase 2 clinical study (MASTERS-1) of its proprietary MultiStem cell therapy for the treatment of ischemic stroke and is preparing for a registrational Phase 3 study that will be conducted in the U.S., Europe and Canada.

"The need for safe, effective and clinically-practical treatments for ischemic stroke patients has never been greater," said Kiyohiro Houkin of Hokkaido University Hospital.

Based on the clinical results from the recently completed MASTERS-1 Phase 2 clinical study, many believe that innovative treatments like MultiStem cell therapy hold great promise for treating the devastating effects of a stroke and helping patients recover more effectively.

Given the rapidly expanding aging population both in Japan and globally, safe and effective treatments that can reach a greater number of stroke victims "could make a significant difference for many patients and their families," Houkin said.

The presentation was delivered at the International Stroke Conference 2017 in Houston, Texas, by Houkin.

He provided an overview of the treatment evaluation of acute stroke using regenerative cell elements (TREASURE) study, which is the Phase 2/3 trial of MultiStem (HLCM051) being conducted by Healios K.K. in Japan.

In conjunction with the conference, Athersys also announced an informational video featuring former NFL player and stroke survivor Tedy Bruschi.

The video (see link below) focuses on the potential of increasing the post-ischemic stroke treatment window while chronicling the challenges facing doctors with today's limited options. CBS broadcaster Solomon Wilcots moderates the video that includes stories of both Bruschi and a Houston stroke survivor who participated in the MASTERS-1 study.



COPYRIGHT 2017 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:In The Clinic ...
Publication:Stem Cell Business News
Geographic Code:9JAPA
Date:Mar 6, 2017
Previous Article:First patient treated with promising bone marrow cell therapy for heart failure.
Next Article:Positive clinical trial results in stem cell selection technology for transplantation.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters